235 related articles for article (PubMed ID: 26191250)
21. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
22. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients.
Cheng H; Sun N; Sun X; Chen B; Li F; Feng J; Cheng L; Cao Y
Acta Biochim Biophys Sin (Shanghai); 2010 May; 42(5):311-7. PubMed ID: 20458443
[TBL] [Abstract][Full Text] [Related]
24. hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment.
Vageli DP; Zaravinos A; Daniil Z; Dahabreh J; Doukas SG; Spandidos DA; Gourgoulianis KI; Koukoulis GK
Int J Biol Markers; 2013 Jan; 27(4):e400-4. PubMed ID: 22865300
[TBL] [Abstract][Full Text] [Related]
25. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.
Watanabe Y; Ueda H; Etoh T; Koike E; Fujinami N; Mitsuhashi A; Hoshiai H
Anticancer Res; 2007; 27(3B):1449-52. PubMed ID: 17595760
[TBL] [Abstract][Full Text] [Related]
26. In vitro study of human mutL homolog 1 hypermethylation in inducing drug resistance of esophageal carcinoma.
Cao Y; Chen Y; Huang Y; Liu Z; Li G
Ir J Med Sci; 2017 May; 186(2):257-263. PubMed ID: 26782688
[TBL] [Abstract][Full Text] [Related]
27. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
28. Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance.
Kouso H; Yoshino I; Miura N; Takenaka T; Ohba T; Yohena T; Osoegawa A; Shoji F; Maehara Y
J Surg Oncol; 2008 Oct; 98(5):377-83. PubMed ID: 18646042
[TBL] [Abstract][Full Text] [Related]
29. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
30. A polymorphism in the hMLH1 gene (-93G-->A) associated with lung cancer susceptibility and prognosis.
Shih CM; Chen CY; Lee IH; Kao WT; Wang YC
Int J Mol Med; 2010 Jan; 25(1):165-70. PubMed ID: 19956916
[TBL] [Abstract][Full Text] [Related]
31. Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy.
Pernía O; Belda-Iniesta C; Pulido V; Cortes-Sempere M; Rodriguez C; Vera O; Soto J; Jiménez J; Taus A; Rojo F; Arriola E; Rovira A; Albanell J; Macías MT; de Castro J; Perona R; Ibañez de Caceres I
Epigenetics; 2014 Nov; 9(11):1446-53. PubMed ID: 25482372
[TBL] [Abstract][Full Text] [Related]
32. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
33. [Status of methylation of promoter of mis-match repair gene hMLH1 in lung cancer].
Chen G; Liu T; He J
Zhonghua Zhong Liu Za Zhi; 2000 Nov; 22(6):493-5. PubMed ID: 11235573
[TBL] [Abstract][Full Text] [Related]
34. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
[TBL] [Abstract][Full Text] [Related]
35. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Nakano K; Taniyama K; Miyata Y; Ohdan H; Okada M
Cancer; 2013 Feb; 119(4):792-8. PubMed ID: 23335114
[TBL] [Abstract][Full Text] [Related]
36. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
[TBL] [Abstract][Full Text] [Related]
37. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.
Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M
Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235
[TBL] [Abstract][Full Text] [Related]
38. hMLH1 promoter methylation is an early event in oral cancer.
González-Ramírez I; Ramírez-Amador V; Irigoyen-Camacho ME; Sánchez-Pérez Y; Anaya-Saavedra G; Granados-García M; García-Vázquez F; García-Cuellar CM
Oral Oncol; 2011 Jan; 47(1):22-6. PubMed ID: 21075045
[TBL] [Abstract][Full Text] [Related]
39. DNMT1 promotes cell proliferation via methylating hMLH1 and hMSH2 promoters in EGFR-mutated non-small cell lung cancer.
Wu XY; Chen HC; Li WW; Yan JD; Lv RY
J Biochem; 2020 Aug; 168(2):151-157. PubMed ID: 32211850
[TBL] [Abstract][Full Text] [Related]
40. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
